- Email: [email protected]
Premenstrual changes and reproductive-related depressions
J. J, Strain and J. C. B. Holland
of CY have been examined also in mice subjected to other stressor paradigms (behavioral despair and physical restraint), and do not produce effects as evident and reproducible as those observed when SD is applied. These results indicate that psychological stressors can control tumor metastasis by host’s antitumor resistance factors through neuroendocrine mechanisms. These factors appear relevant for tumor spread and curability by antitumor agents, with implications of interest for experimental and clinical situations.
Premenstrual Changes and Reproductive-Related Depressions Leslie Hartley Gise, Patricia L. Puddison, Lisa Robinson, Maria Russo, Jumes J. Strain Mount Sinai School of Medicine, New York, NY Of 346 women seeking treatment for premenstrual symptoms, 48 (14%) had a premenstrual disorder prospectively confirmed using the NIMH criteria of 1983 and the Late Luteal Phase Dysphoric Disorder criteria of DSM-III-R. Using a logistic regression analysis, women with a prospectively confirmed premenstrual disorder differed from others with regard to duration of illness (p = O.Ol), past treatment for premenstrual symptoms (p < 0.05), and beliefs about their health (p < 0.05). Other demographic, clinical, and psychologic variables failed to distinguish women with a prospectively confirmed premenstrual disorder from others complaining of premenstrual symptoms. Twenty percent (69/346) had a past history of a major depressive episode following the use of oral contraceptive agents and were younger (p < .05) and more likely to have a family history of mental illness or alcoholism (p < .Ol). Twenty-two percent (76/346) had a past history of a major depressive episode postpartum and were more likely to be married (p = 0.0001) with poorer marital adjustment (p < 0.01). These data emphasize the need for prospective documentation in order to diagnose a premenstrual disorder. Although reproductive-related depressions were not uncommon among women seeking treatment for premenstrual symptoms, they did not predict a prospectively confirmed premenstrual disorder. Further study of past and family history of depression as well as marital status and marital adjustment among women with reproductive-related depressions is needed.
Efficacy of Pharmacological Treatment of Anxiety in HIV-Positive Asymptomatic Men Dun Alan Hirsch, Joanne Fishman, Paul Jacobsen, Jimmie Holland, William Breitburt Psychiatry Service, Memorial Sloan-Kettering Cancer Center, New York, NY Reactive anxiety is a profound problem for those individuals diagnosed as HIV seropositive, and conventional anxiolytic agents often produce significant adverse side effects, such as sedation. We have examined the efficacy of buspirone, in the treatment of anxiety in HIV-positive, asymptomatic gay men. Ten of a planned sample of 35 HIV-positive, asymptomatic gay men have been entered into an 8-week, doubleblind, placebo-controlled clinical trial of buspirone. The average study subject is a white, 36-year-old, exclusively homosexual male. Fifty-five percent of the sample were engaged in a full-time personal relationship and are currently employed full time. Two-thirds of the sample qualified for a DSM-III-R diagnosis of generalized anxiety disorder, and the remaining subjects received a diagnosis of an adjustment disorder with anxious or mixed features. Weekly assessments are utilized to evaluate a spectrum of psychological symptoms, compliance with medication regimen, healthrelated behaviors, and health locus of control. Due to the unique anxiolytic activity and low side-effect profile of buspirone, this medication would appear to be an ideal agent for the treatment of anxiety in HIV-seropositive individuals. Data on the efficacy of the medication in reducing psychological distress will be presented. Implications for the use of psychopharmacological intervention in thispopulation will be discussed.
372
of CY have been examined also in mice subjected to other stressor paradigms (behavioral despair and physical restraint), and do not produce effects as evident and reproducible as those observed when SD is applied. These results indicate that psychological stressors can control tumor metastasis by host’s antitumor resistance factors through neuroendocrine mechanisms. These factors appear relevant for tumor spread and curability by antitumor agents, with implications of interest for experimental and clinical situations.
Premenstrual Changes and Reproductive-Related Depressions Leslie Hartley Gise, Patricia L. Puddison, Lisa Robinson, Maria Russo, Jumes J. Strain Mount Sinai School of Medicine, New York, NY Of 346 women seeking treatment for premenstrual symptoms, 48 (14%) had a premenstrual disorder prospectively confirmed using the NIMH criteria of 1983 and the Late Luteal Phase Dysphoric Disorder criteria of DSM-III-R. Using a logistic regression analysis, women with a prospectively confirmed premenstrual disorder differed from others with regard to duration of illness (p = O.Ol), past treatment for premenstrual symptoms (p < 0.05), and beliefs about their health (p < 0.05). Other demographic, clinical, and psychologic variables failed to distinguish women with a prospectively confirmed premenstrual disorder from others complaining of premenstrual symptoms. Twenty percent (69/346) had a past history of a major depressive episode following the use of oral contraceptive agents and were younger (p < .05) and more likely to have a family history of mental illness or alcoholism (p < .Ol). Twenty-two percent (76/346) had a past history of a major depressive episode postpartum and were more likely to be married (p = 0.0001) with poorer marital adjustment (p < 0.01). These data emphasize the need for prospective documentation in order to diagnose a premenstrual disorder. Although reproductive-related depressions were not uncommon among women seeking treatment for premenstrual symptoms, they did not predict a prospectively confirmed premenstrual disorder. Further study of past and family history of depression as well as marital status and marital adjustment among women with reproductive-related depressions is needed.
Efficacy of Pharmacological Treatment of Anxiety in HIV-Positive Asymptomatic Men Dun Alan Hirsch, Joanne Fishman, Paul Jacobsen, Jimmie Holland, William Breitburt Psychiatry Service, Memorial Sloan-Kettering Cancer Center, New York, NY Reactive anxiety is a profound problem for those individuals diagnosed as HIV seropositive, and conventional anxiolytic agents often produce significant adverse side effects, such as sedation. We have examined the efficacy of buspirone, in the treatment of anxiety in HIV-positive, asymptomatic gay men. Ten of a planned sample of 35 HIV-positive, asymptomatic gay men have been entered into an 8-week, doubleblind, placebo-controlled clinical trial of buspirone. The average study subject is a white, 36-year-old, exclusively homosexual male. Fifty-five percent of the sample were engaged in a full-time personal relationship and are currently employed full time. Two-thirds of the sample qualified for a DSM-III-R diagnosis of generalized anxiety disorder, and the remaining subjects received a diagnosis of an adjustment disorder with anxious or mixed features. Weekly assessments are utilized to evaluate a spectrum of psychological symptoms, compliance with medication regimen, healthrelated behaviors, and health locus of control. Due to the unique anxiolytic activity and low side-effect profile of buspirone, this medication would appear to be an ideal agent for the treatment of anxiety in HIV-seropositive individuals. Data on the efficacy of the medication in reducing psychological distress will be presented. Implications for the use of psychopharmacological intervention in thispopulation will be discussed.
372